Clinical Trials Browser

Urinary Bladder Neoplasms

NCT05092958 2026-04-21

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

654 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT03076554 2026-04-20

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

Phase 2 Active not recruiting

56 enrolled

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

NCT03971409 2026-04-17

InCITe

Phase 2 Active not recruiting

145 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Phase 3 Active not recruiting

68 enrolled

Gynecologic

Ovarian Neoplasms

NCT03271372 2026-04-13

ADAM

Phase 3 Active not recruiting

101 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT04068194 2026-04-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Phase 1/2 Active not recruiting

103 enrolled

Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT05947500 2026-04-13

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

Phase 2 Active not recruiting

50 enrolled

Dermatologic

Carcinoma, Merkel Cell

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT04291885 2026-04-09

I-MAT

Phase 2 Active not recruiting

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Phase 2 Active not recruiting

18 enrolled

Dermatologic

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

205 enrolled

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

Phase 1 Active not recruiting

210 enrolled

DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

NCT04261855 2026-03-27

GoTHAM

Phase 1/2 Active not recruiting

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

Clinical Trials

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

InCITe

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

ADAM

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

I-MAT

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

Avelumab Program Rollover Study

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

GoTHAM